Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592288 | 0.88 | CYP11B1 (0.50) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL21592248 | 0.87 | CYP19A1 (0.46) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL21592266 | 0.87 | ALDH1A1 (0.41) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL21592284 | 0.83 | CYP19A1 (0.47) | ATMMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL21591502 | 0.81 | CYP11B1 (0.59) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL21592279 | 0.79 | KCNA5 (0.44) | L3MBTL1HSD17B10 | |
| SCHEMBL21591454 | 0.79 | CYP11B1 (0.58) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL21592239 | 0.76 | IDH1 (0.46) | KMT2A | |
| SCHEMBL21591521 | 0.75 | CYP11B1 (0.56) | CYP19A1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL21592240 | 0.74 | KMT2A (0.49) | MEN1KMT2ACYP19A1CYP11B1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | NPC1 2744/4885RAB9A 2670/4885ATM 418/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | NPC1 2744/4885RAB9A 2670/4885ATM 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.